Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

231 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The role of PET in the management of sarcoidosis.
Vender RJ, Aldahham H, Gupta R. Vender RJ, et al. Curr Opin Pulm Med. 2022 Sep 1;28(5):485-491. doi: 10.1097/MCP.0000000000000892. Epub 2022 Jul 16. Curr Opin Pulm Med. 2022. PMID: 35869739 Free PMC article. Review.
Real-World Effectiveness and Safety of Risankizumab in Adult Patients with Plaque Psoriasis: A 1-year International Multicenter Retrospective Cohort Study.
Bagit A, Maliyar K, Mansour M, Georgakopoulos JR, Rankin B, Lytvyn Y, Zaaroura H, Park YJ, Wang E, Mufti A, Torres T, Le AM, Vender R, Prajapati VH, Yeung J. Bagit A, et al. Among authors: vender r. J Am Acad Dermatol. 2024 Apr 25:S0190-9622(24)00654-6. doi: 10.1016/j.jaad.2024.03.048. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 38677338 No abstract available.
Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 16-week multicenter retrospective study.
Rimke A, Sood S, Rankin BD, Abduelmula A, Georgakopoulos JR, Maliyar K, Bagit A, Leung F, Stark LA, Vender R, Yeung J, Prajapati VH. Rimke A, et al. Among authors: vender r. J Am Acad Dermatol. 2024 Apr 20:S0190-9622(24)00642-X. doi: 10.1016/j.jaad.2024.04.027. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 38649098 No abstract available.
Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor).
Gooderham M, Vender R, Crowley J, Hong HC, Feely M, Garrelts A, See K, Konicek B, Green L. Gooderham M, et al. Among authors: vender r. Dermatol Ther (Heidelb). 2024 Feb;14(2):441-451. doi: 10.1007/s13555-023-01075-y. Epub 2024 Feb 9. Dermatol Ther (Heidelb). 2024. PMID: 38332436 Free PMC article.
An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis.
Bissonnette R, Pinter A, Ferris LK, Gerdes S, Rich P, Vender R, Miller M, Shen YK, Kannan A, Li S, DeKlotz C, Papp K. Bissonnette R, et al. Among authors: vender r. N Engl J Med. 2024 Feb 8;390(6):510-521. doi: 10.1056/NEJMoa2308713. N Engl J Med. 2024. PMID: 38324484 Clinical Trial.
231 results